Key Market Indicators
Sales of blood and blood forming organs medicine in the Czech Republic are expected to reach $523.4 million by 2026, up from $455.7 million in 2021. This equates to an average annual growth rate of 2.2% since 1995. In 2021, the Czech Republic was the 13th largest market for this type of medicine, with Switzerland in the lead at $455.7 million. Germany, Italy, and South Korea ranked 2nd, 3rd, and 4th respectively. The prevalence of anemia in the Czech Republic is projected to reach 13,930 hospital discharges by 2026, up from 12,600 in 2021. This equates to an average annual growth rate of 1.7% since 2005. In 2021, the Czech Republic was the 12th largest market for this type of medicine, with the Netherlands in the lead at 12,600 hospital discharges. Germany, the United Kingdom, and Poland ranked 2nd, 3rd, and 4th respectively.
